Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

BackgroundThe MET proto-oncogene (MET) plays a crucial role as an oncogenic driver gene in non-small cell lung cancer (NSCLC). At present, numerous types of MET exon 14 (METex14) skipping mutation have been identified, but different splice variants often exhibit varying treatment responses. There is...

Full description

Saved in:
Bibliographic Details
Main Authors: Yinyin Xue, Wen Li, Pengfei Li, Kaili Huang, Qinghua Zhou, Qiang Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
novel MET exon 14 skipping mutation
EGFR-TKI resistance
advanced lung adenocarcinoma
savolitinib
sustained clinical response
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1489696/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items